Rx Insights: October '26 Recap

Expion Health
Expion Health
November 18, 2026
•
5 min read

This month’s edition provides a focused review of newlyapproved and recently launched therapies. Expion Health monitors thesedevelopments closely to assess clinical relevance, therapeutic positioning, andpotential implications for payers, providers, and patients.

HIBSAGO™

Indication

HIBSAGO is indicated for the treatment of chronic hepatitis B (CHB) in adults who donot have cirrhosis (advanced liver disease). It is administered in combination with nucleos(t)ide analogue reverse transcriptase inhibitors (NRTIs), such asentecavir or tenofovir, which are used as antiviral therapy for hepatitis B.

Dosage and Administration

HIBSAGOis available as 150mg injection. It is administered at a dose of 300mg twice aweek, allowing 3 to 4 days between each dose and 300mg once a week (same day ofthe week) weeks 3 to 24. Dosing should be based on liver, platelet, and kidneyblood tests. Maximum treatment length is 24 weeks.

Warnings and Precautions

HIBSAGOcontains a boxed warning for liver enzyme flare-ups and low platelet counts. Itmay also cause worsening kidney function and can lead to inflammatory orimmune-mediated conditions, including inflammation of blood vessels. Othercommon side effects include injection site reactions, fever, tiredness, andheadache.

Mechanism of Action

HIBSAGOis an antisense oligonucleotide (ASO) that works by targeting the hepatitis Bvirus (HBV) genetic material (RNA) within liver cells. By reducing theproduction of the virus and its proteins, including hepatitis B surface antigen(HBsAg), HIBSAGO helps lower viral activity in the liver.

Disease Background

Hepatitis Bresults in inflammation of the liver caused by the Hepatitis B virus, whichspreads through contact with infected blood. Despite the widespreadavailability of hepatitis B vaccines, HBV-related hospitalizations, livercancer cases, and deaths in the United States have more than doubled over thepast decade. An estimated 850,000 people in the United States are living withchronic HBV infection. The prevalence is two to three times higher amongnon-Hispanic Black individuals than in the general population. When recentimmigrants are included, some estimates suggest that as many as 2.2 millionpeople in the United States may be living with chronic hepatitis B.

Clinical Data

FDA approval of HIBSAGO is based on the Phase 3 B-Well 1 and B-Well 2 studies. At Week72, functional cure rates in the Phase 3 B-Well 1 and B-Well 2 trials were 20%and 19% among HIBSAGO-treated patients, while no patients in the placebo groups achieved a functional cure. Functional cure required maintenance of HBVDNA suppression and HBsAg loss for 24 weeks following the end of all HBV treatment.

Clickto view package insert.

HOVILPRI®

Indication

HOVILPRI is FDA approved to treat lesions caused by herpes simplex virus (HSV)infection, which did not improve after treatment with acyclovir, valacycloviror famciclovir, in immunocompromised adults. HOVILPRI does not cure HSVinfection.

Dosage and Administration

The recommendeddose for HOVILPRI is four 100mg tablets as a single dose on day 1.Starting day 2, one 100mg tablet should be taken once daily. HOVILPRIshould be taken as directed by the healthcare provider until HSV lesions havecompletely healed.

Warnings and Precautions

The most commonside effect for HOVILPRI is headache. Anyone pregnant or breastfeedingshould notify their healthcare provider prior to treatment. Patients shouldnotify healthcare providers about all medicines taken, including prescriptionand over-the-counter medicines, vitamins, and herbal supplements. It is notknown if HOVILPRI is safe and effective in children less than 18 yearsof age.

Mechanism of Action

HOVILPRIis an antiviral agent that inhibits the HSV helicase-primase complex, anessential enzyme complex involved in unwinding and replicating viral DNA. Bydisrupting this replication process, HOVILPRI prevents the production ofnew viral DNA in both HSV-1 and HSV-2. Because it acts through a mechanismdistinct from acyclovir and foscarnet, it remains effective against HSV strainsresistant to nucleoside analogs or foscarnet, and cross-resistance is notexpected.

Disease Background

Herpes simplexvirus (HSV) is a double-stranded DNA virus that causes orofacial herpes,primarily associated with HSV-1, and genital herpes, most commonly caused byHSV-2. In the United States, the estimated seroprevalence among individualsaged 14 to 49 years in 2016 was 47.8% for HSV-1 and 11.9% for HSV-2. Whilerecurrent genital herpes has traditionally been linked to HSV-2 infection,HSV-1 is increasingly recognized as a cause of anogenital herpes, particularlyamong young women and men who have sex with men (MSM). Additionally, genitalHSV-2 infection is associated with a two- to threefold increased risk ofacquiring HIV. Effective control of HSV depends on a competent immune system.Consequently, immunocompromised individuals are at greater risk for HSVreactivation and may experience more severe, prolonged, or recurrent episodesof oral, genital, or perianal herpes. Compared with immunocompetentindividuals, recurrences in immunocompromised patients are often more frequent,extensive, and persistent. Chronic mucocutaneous HSV infections in thispopulation may also invade deeper layers of the skin, resulting in tissuenecrosis, significant pain, and atypical clinical presentations.

Clinical Data

FDA-approval was supported by results from the Phase 3 PRIOH-1 trial, which demonstrated that HOVILPRI achieved significantly higher rates of complete lesionhealing compared with investigator-selected treatment options, including intravenous foscarnet, intravenous or topical cidofovir, or topical imiquimod. At Day 28, complete lesion healing was observed in 63% of patients treated with HOVILPRI versus 34% of those receiving investigator’s choice therapy(P=0.0047). By Day 42, healing rates increased to 82% and 42%, respectively.Treatment-emergent adverse reactions were also less common with HOVILPRI than with comparator therapies (22% vs 54%).

Click to view package insert.

‍

Build pharmacy forward from your inbox

Get the insights shaping what’s next in prescription economics, market pressure and pharmacy strategy.

By subscribing you agree to our Privacy Policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
What to Read Next

For the teams building pharmacy forward

Get the Expion Health® perspective on the trends, decisions, and market shifts redefining how pharmacy value is created.

No items found.

Move beyond the pharmacy black box

See how Expion helps organizations build pharmacy strategies with more visibility, flexibility and control from the start.